PDF
ePub
Citation
Print
Abstract
Purpose
This study was aimed at evaluating the recurrence rate and recurrence patterns after surgically treating for patients with operable breast cancer.
Methods
From 1992 to 2002, 3700 patients with breast cancer (stages 0-3) who underwent mastectomy or breast conservation surgery at Asan Medical Center, Seoul, were selected for this retrospective study. We analyzed the recurrence rate, the annual hazard rate, the risk factors, the time to recurrence and the recurrence patterns according to the clinicopathologic factors.
Results
During the median follow-up period of 45 months, 523 patients (14.1%) of the total 3700 patients developed recurrences: locoregional recurrences occurred in 148 patients (4.0%), distant recurrences occurred in 319 patients (8.6%), and both types occurred in 56 patients (1.5%). The 5-year and 10-year recurrence rates were 17.7% and 23.4%, respectively. The recurrence rate increased in proportion to the cancer stage. The annual hazard rate for recurrence had a peak at 2-years of follow-up. On multivariate analysis, the stage, progesterone receptor status, and c-erbB2 expression were the independent risk factors for recurrence. The median time to recurrence among the patients with recurrence was 24.0 months. 50.5% of recurrences were found within 2 years and 92.0% of recurrences were found within 5 years after surgery. A short time to recurrence was significantly associated with an increased stage, a negative progesterone receptor status, and locoregional recurrences. The common recurrence sites included the chest wall, SCLN and the axillary lymph nodes in a locoregional order, and the bone, lung and liver in a systemic order. Of note is that distant recurrences commonly occurred at multiple sites in a simultaneous manner.
Conclusion
Our findings revealed that the 5 year-recurrence rate was 17.7% and the risk of recurrence was maintained 5 years later after surgery, although the annual hazard rate had the highest peak at 2 years after breast cancer surgery. Because the stage, progesterone receptor status, and c-erbB2 expression are independent risk factors, early detection of breast cancer is required for reducing recurrence.
References
1. Horst KC, Smitt MC, Goffinet DR, Carlson RW. Predictors of local recurrence after breast-conservation therapy. Clin Breast Cancer. 2005. 5:425–438.
2. Huston TL, Simmons RM. Locally recurrent breast cancer after conservation therapy. Am J Surg. 2005. 189:229–235.
3. Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001. 19:1688–1697.
4. Arriagada R, Le MG, Contesso G, Guinebretiere JM, Rochard F, Spielmann M. Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer. Ann Oncol. 2002. 13:1404–1413.
5. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2002, Featuring population-based trends in cancer treatment. J National Cancer Institute. 2005. 97:1407–1427.
6. Korean Central Cancer Registry. 2002 Annual report of the Korean Central Cancer Registry. 2003. Gwacheon: Ministry of Health and Welfare.
7. Korean Breast Cancer Society. Nationwide Korean breast cancer data of 2002. J Korean Breast Cancer Soc. 2004. 7:72–83.
8. Im TH, Jung PJ. The patterns, the survival, and the change of serologic markers after recurrence in patients with breast cancer. J Korean Surg Soc. 1998. 54:313–322.
9. Park KH, Kim SI, Ko SS, Park BW, Lee KS. The patterns of systemic failure and factors influencing on the outcome after distant metastasis in breast cancer. J Korean Breast Cancer Soc. 2003. 6:109–116.
10. Paik NS, Noh WC, Bang HY, Hwang DY, Choi DW, Lee JI, et al. Recurrence following breast conserving therapy. J Korean Breast Cancer Soc. 2000. 1:64–75.
11. Kang SH, Chung KY, Kim YS, Kim JH. Disease free survival and prognostic factors for patients with breast conserving surgery. J Korean Surg Soc. 2004. 67:274–278.
12. Jatoi I, Tsimelzon A, Weiss H, Clark GM, Hilsenbeck SG. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat. 2005. 89:173–178.
13. Baum M, Badwe RA. Johnson H, editor. Does surgery influence the natural history of breast cancer? Breast cancer: controversies in management. 1994. Armonk, NY: Futura Pub;61–69.
14. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat. 1996. 41:177–185.
15. Gasparini G, Biganzoli E, Bonoldi E, Morabito A, Fanelli M, Boracchi P. Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy. Breast Cancer Res Treat. 2001. 65:71–75.
16. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999. 91:80–85.
17. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996. 14:2738–2746.
18. Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy. Cancer. 1978. 41:1170–1178.
19. Bland KI, Copeland EM III. Schwartz SI, Shires GT, Spencer FC, editors. Breast. Principles of surgery. 1994. 6th ed. New York: McGraw-Hill;554–557.
20. Hiramanek N. Breast cancer recurrence: follow-up after treatment for primary breast cancer. Postgrad Med J. 2004. 80:172–176.
21. Ernst MF, Voogd AC, Coebergh JW, Poortmans PM, Roukema JA. Using loco-regional recurrence as an indicator of the quality of breast cancer treatment. Eur J Cancer. 2004. 40:487–493.
22. Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I Through VII. J Clin Oncol. 2003. 21:1205–1213.
23. Son BH, Lee PC, Yoon HS, Kwak HS, Lee KC, Kim CS, et al. Patterns of locoregional and systemic failure after a mastectomy in breast cancer and risk factors predicting failure. J Korean Surg Soc. 2000. 59:305–312.
24. Lee JB, Kim DH, Min BW, Ryu KW, Um JW, Kim AR, et al. Factors influencing the recurrence of breast cancer following modified radical mastectomy. J Korean Breast Cancer Soc. 2001. 4:128–135.
25. Kang SH, Chung KY, Kim YS, Kim JH. Disease free survival and prognostic factors for patients with breast conserving surgery. J Korean Surg Soc. 2004. 67:274–278.
26. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003. 349:1793–1802.
27. Kamby C, Anderson J, Ejlertsen B, Birkler NE, Rytter L, Zedeler K, et al. Pattern of spread and progression in relation to the characteristics of the primary tumor in human breast cancer. Acta Oncol. 1991. 30:301–308.
28. Blanco G, Holli K, Heikkinen M, Kallioniemi OP, Taskinen P. Prognostic factors in breast cancer. Br J Cancer. 1990. 62:142–146.
29. de Bock GH, van der Hage JA, Putter H, Bonnema J, Bartelink H, van der Velde CJ. Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organization for Research and Treatment of Cancer studies. Eur J Cancer. 2006. 42:351–356.
XML Download